PanMediso Spotlight｜Dynamics of Radiopharmaceuticals Business

Recently, a number of notable progress have been made in radiopharmaceuticals business both at home and abroad.

l Chongqing Pharmaceutical Group.yimao MEDICAL Trade Co., Ltd. has successfully obtained a licence from the Chongqing Municipal Drug Administration for the operation of nuclear drugs。

l The Affiliated Cancer Hospital of Shandong Medical University has become the first medical unit in Shandong to have a licence for the use of top-class radiopharmaceuticals in China.

l ITM (Isotopen Technologien München) was granted a wholesale licence in the United States, securing the qualification of radiopharmaceutical distribution.

These milestones signify that the radiopharmaceutical industry is moving towards a new stage of development, providing new opportunities for precision diagnosis and treatment in nuclear medicine.

Chongqing Pharmaceutical Group: Opening a new track in nuclear drug business

Yimao MEDICAL Trade Co.,Ltd., a subsidiary of Chongqing Pharmaceutical Group, has successfully obtained the Radioactive Drug Operation Licence issued by Chongqing Municipal Drug Administration, creating a new development channel in the circulation of nuclear drug operation. The acquisition of the licence enabled the Group to initially established its leading position in nuclear medicine business.

The Affiliated Cancer Hospital of Shandong Medical University: Benchmark of Nuclear Medicine Department Construction

The Department of Nuclear Medicine of the hospital was successfully approved the Licence for the Use of Radioactive Pharmaceuticals (Class IV), becoming the first Grade IIIA medical unit in Shandong with the qualification of the use of top-class radioactive pharmaceuticals in the domestic industry, which marks that the hospital has built a systematic and standardised platform for the research and development and clinical transformation of new radioactive drugs and provides strong support for the accurate diagnosis and treatment of tumour patients with nuclear medicine. The expert group of Shandong Food and Drug Administration fully affirmed the construction and development of the hospital, calling it a benchmark for standardised construction and high-quality development of nuclear medicine discipline in the province.

ITM (Isotopen Technologien München): wholesale licence approved in the USA

ITM has announced that it has been granted a wholesale licence by the New Jersey Department of Health, marking its to operate as a virtual manufacturer. It's a critical step for ITM to secure this license for its business activities in the United States,, allowing the company to distribute its radiopharmaceutical products. And it is also a crucial step in ITM's expansion of its presence in the United States to it for the future launch of its diagnostic and therapeutic radiopharmaceuticals in the region, according to ITM's Chief Executive Officer, Steffen Schuster.

This series of progress signifies that the operation of the global radiopharmaceuticals is steadily entering a standardised stage, and the layout of various enterprises in different countries and regions will provide robust support for further innovation and development of the industry. Pamedic Holdings is convinced that radiopharmaceuticals will play an even more significant role in the medical field as technology advances and cooperation deepens. In the future, we will keep working closely with our international counterparts to promote the development of the radiopharmaceutical industry and help radiopharmaceutical industry to move towards a brilliant future.

Pamedic Spotlight｜Dynamics of Radiopharmaceuticals Business